Summarized by Masters of Longevity from Longevity Docs News.
ARO-MAPT: a news article previewing clinical trial interim results of a subcutaneous RNAi therapy that reduced cerebrospinal fluid tau in volunteers, discussing trial design and implications.
Key Takeaways
- ARO-MAPT lowered cerebrospinal fluid total tau by a mean 40% to 73% in healthy volunteers measured 90 days after last dose.
- The trial AROMAPT-SC-1001 is a placebo-controlled, dose-escalating study in about 64 healthy volunteers with up to 48 early Alzheimer’s participants planned.
- Arrowhead reported the data and positions the subcutaneous RNAi formulation as potentially dosable every three months with Alzheimer's data expected in 2027.
